Erudio Healtherudio.com
Sponsor
UNICANCER trials: what clinicians said in public
No HCP commentary report on a trial sponsored by UNICANCER yet. Erudio has found public clinician commentary on 18 clinical trials sponsored by UNICANCER, including ALBAN, MOIO, PADA-1 and PRODIGE-24. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (UNICANCER). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PADA-1 NCT03079011 · UNICANCER DeepView → | ER-positive, HER2-negative metastatic breast cancer with ESR1 mutation | Phase 3 | Deep | View | |||
| ALBAN NCT03799835 · UNICANCER DeepView → | BCG-naive high-risk non-muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| PRODIGE-24 NCT01526135 · UNICANCER DeepView → | resected pancreatic adenocarcinoma | Phase 3 | Deep | View | |||
| MOIO NCT05078047 · UNICANCER DeepView → | locally advanced or metastatic cancer | Phase 3 | Deep | View | |||
| PRODIGE 7 NCT00769405 · UNICANCER DeepView → | colorectal peritoneal metastases | Phase 3 | Deep | View | |||
| PRODIGE 4 NCT00112658 · UNICANCER DeepView → | first-line metastatic pancreatic adenocarcinoma | Phase 2/Phase 3 | Deep | View | |||
| NEOPAN NCT02539537 · UNICANCER DeepView → | locally advanced pancreatic carcinoma | Phase 3 | Deep | View | |||
| CHIPOR NCT01376752 · UNICANCER StandardView → | recurrent ovarian cancer | Phase 3 | Standard | View | |||
| PEACE-1 NCT01957436 · UNICANCER StandardView → | de novo metastatic castration-sensitive prostate cancer | Phase 3 | Standard | View | |||
| NIVOREN NCT03013335 · UNICANCER StandardView → | metastatic clear cell renal cell carcinoma | Phase 2 | Standard | View | |||
| PRESTO NCT04115007 · UNICANCER StandardView → | oligometastatic hormone-sensitive prostate cancer | Phase 3 | Standard | View | |||
| AMBRE NCT04158362 · UNICANCER StandardView → | high burden ER+/HER2- breast cancer with visceral metastasis | Phase 3 | Standard | View | |||
| ARION NCT03777813 · UNICANCER FocusedView → | localised unresectable esophageal cancer | Phase 2 | Focused | View | |||
| GETUG-AFU22 NCT01994239 · UNICANCER FocusedView → | prostate adenocarcinoma with detectable PSA after prostatectomy | Phase 2 | Focused | View | |||
| GETUG-AFU 31 NCT03438552 · UNICANCER FocusedView → | intraprostatic tumor recurrence after external radiation therapy | Not applicable | Focused | View | |||
| ETNA NCT06078384 · UNICANCER FocusedView → | resected early triple-negative breast cancer with high TILs | Phase 2 | Focused | View | |||
| NCT01804790 NCT01804790 · UNICANCER FocusedView → | resectable locally advanced rectal cancer | Phase 3 | Focused | View | |||
| PEACE6-Vulnerable NCT04916613 · UNICANCER FocusedView → | de novo metastatic prostate cancer, vulnerable functional ability | Phase 3 | Focused | View | |||